tiprankstipranks
Trending News
More News >
Vitalhub (TSE:VHI)
TSX:VHI

Vitalhub (VHI) AI Stock Analysis

Compare
180 Followers

Top Page

TS

Vitalhub

(TSX:VHI)

Rating:73Outperform
Price Target:
C$12.00
▲(10.40%Upside)
Vitalhub's strong financial performance is the most significant factor, highlighting robust revenue growth and a solid capital structure. Positive corporate events further bolster the company's future prospects. However, the high P/E ratio suggests potential overvaluation, warranting caution for value investors. Moderate technical indicators indicate balanced market sentiment.

Vitalhub (VHI) vs. iShares MSCI Canada ETF (EWC)

Vitalhub Business Overview & Revenue Model

Company DescriptionVitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination, patient flow and operational visibility, and mobile apps. The company was incorporated in 2010 and is based in Toronto, Canada.
How the Company Makes MoneyVitalhub makes money primarily through the sale of its software solutions to healthcare providers. The company's revenue model includes licensing fees, subscription fees, and service contracts for its software products. Key revenue streams involve long-term contracts with hospitals, mental health organizations, and other healthcare facilities that utilize Vitalhub's technology to streamline their operations and improve patient care. Additionally, Vitalhub may generate revenue through strategic partnerships with other technology firms and healthcare providers, which can expand its market reach and offer integrated solutions to clients.

Vitalhub Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q3-2024)
|
% Change Since: -8.35%|
Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth, successful acquisitions, and a solid financial position with no debt. However, there were concerns about a slight decrease in services revenue and potential short-term impacts on margins due to recent acquisitions. Overall, the positive aspects, including the strategic acquisitions and revenue growth, outweighed the lowlights.
Q3-2024 Updates
Positive Updates
Strong Revenue Growth
Total revenue for Q3 2024 was $16.5 million, reflecting a 25% increase over the prior year period.
Increase in Recurring Revenue
Annual recurring revenue at the end of Q3 2024 was $53.5 million, up 25% from the previous year.
Successful Acquisitions
Completed acquisitions of MedCurrent and Strata Health, adding a combined $14.6 million to ARR, with Strata Health being the largest transaction in the company's history.
Cash Reserves and No Debt
As of September 30, 2024, the company reported cash on hand of $81.4 million and no debt.
High Adjusted EBITDA Margin
The adjusted EBITDA for Q3 2024 was $4.6 million, with a margin of 28%.
Negative Updates
Decrease in Services Revenue
Services, hardware, and other revenue decreased by 1% year-over-year due to slower deployment during the summer quarter.
Potential Margin Impact from Acquisitions
The integration of recent acquisitions might lead to a temporary reset in EBITDA margins over the next few quarters.
Seasonal Challenges in Services
Q3 is typically a light quarter for services due to staff and customer holidays during the summer months.
Company Guidance
During the Q3 2024 earnings call for VitalHub, the company provided guidance highlighting significant growth metrics and strategic developments. Total revenue for the quarter was reported at $16.5 million, marking a 25% increase compared to the same period last year. Recurring revenue, a key focus for the company, reached $53.5 million annually, reflecting a 25% year-over-year growth. The gross margin stood at 81%, slightly down from 82% the previous year. Net income before taxes was $2.4 million, while adjusted EBITDA was $4.6 million, leading to an impressive adjusted EBITDA margin of 28%. The company successfully closed two acquisitions post-quarter: MedCurrent, adding $2.3 million in annual recurring revenue (ARR), and Strata Health, contributing an additional $12.3 million in ARR, bringing the pro forma ARR to $68 million. With over $50 million in cash and no debt, VitalHub is well-positioned to maintain its growth trajectory while integrating these acquisitions.

Vitalhub Financial Statement Overview

Summary
Vitalhub exhibits strong financial health with impressive revenue growth and stable operational efficiency. The company maintains a solid balance sheet with low leverage and substantial equity. Cash flow generation is effective, although there is potential for improving free cash flow efficiency. Overall, the financials reflect a well-managed company with a strong growth trajectory in the healthcare information services sector.
Income Statement
85
Very Positive
Vitalhub demonstrates robust revenue growth with a TTM (Trailing-Twelve-Months) revenue increase from the previous year. The gross profit margin is strong at approximately 78.2%, indicating efficient cost management. Net profit margin, while positive, is moderate at 3.8%, signaling room for improvement in profitability. The EBIT and EBITDA margins are healthy, reflecting good operational efficiency.
Balance Sheet
90
Very Positive
The balance sheet is strong, with a low debt-to-equity ratio of approximately 0.004, indicating minimal leverage and financial risk. The return on equity (ROE) is modest at 1.6%, suggesting potential for higher profitability. The equity ratio is high at 73.4%, highlighting a solid capital structure with significant equity backing.
Cash Flow
80
Positive
Vitalhub's cash flow position is solid, with a high positive operating cash flow. The free cash flow has grown, reflecting effective cash generation. The operating cash flow to net income ratio is robust, indicating strong cash earnings relative to reported income. However, the free cash flow to net income ratio shows some room for improvement, suggesting potential efficiency gains in cash usage.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue75.01M68.59M52.51M39.97M24.66M13.79M
Gross Profit58.69M55.49M42.81M32.94M19.43M10.29M
EBITDA12.30M11.90M10.38M5.25M1.12M148.12K
Net Income2.84M3.00M4.55M1.21M-1.95M-2.17M
Balance Sheet
Total Assets244.53M207.19M118.78M106.19M72.77M64.08M
Cash, Cash Equivalents and Short-Term Investments91.21M56.57M33.48M17.45M16.39M23.39M
Total Debt784.35K608.76K541.09K882.20K792.51K987.89K
Total Liabilities64.83M62.33M36.88M30.79M17.95M13.77M
Stockholders Equity179.70M144.86M81.91M75.40M54.82M50.31M
Cash Flow
Free Cash Flow14.84M14.24M20.18M5.83M-309.58K294.35K
Operating Cash Flow15.73M15.13M20.47M6.12M-49.97K405.14K
Investing Cash Flow-28.71M-31.39M-4.15M-21.84M-10.06M-9.37M
Financing Cash Flow70.70M39.09M-287.89K16.40M3.17M30.37M

Vitalhub Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10.87
Price Trends
50DMA
10.70
Positive
100DMA
10.35
Positive
200DMA
10.39
Positive
Market Momentum
MACD
0.13
Positive
RSI
52.42
Neutral
STOCH
29.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VHI, the sentiment is Positive. The current price of 10.87 is above the 20-day moving average (MA) of 10.77, above the 50-day MA of 10.70, and above the 200-day MA of 10.39, indicating a bullish trend. The MACD of 0.13 indicates Positive momentum. The RSI at 52.42 is Neutral, neither overbought nor oversold. The STOCH value of 29.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VHI.

Vitalhub Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSVHI
73
Outperform
C$586.89M203.182.15%35.97%-59.04%
TSKSI
65
Neutral
C$580.54M-4.56%42.93%85.95%
55
Neutral
C$10.40M-244.35%-71.31%-53.11%
51
Neutral
$7.41B0.36-61.88%2.33%16.99%1.69%
TSADK
24
Underperform
C$19.35M366.78%-35.15%-6.59%
$23.96M-507.20%
$11.69M-9999.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:VHI
Vitalhub
10.87
3.30
43.59%
TSE:ADK
Diagnos
0.19
-0.12
-38.71%
TSE:AIML
Aiml Resources
0.06
0.00
0.00%
TSE:KSI
kneat.com
6.15
1.88
44.03%
TREIF
Treatment.com International
0.29
-0.27
-48.21%
UDOCF
UniDoc Health Corp
0.14
-0.44
-75.86%

Vitalhub Corporate Events

Executive/Board ChangesShareholder Meetings
VitalHub Announces Successful Election of Directors and Auditor Appointment
Positive
Jun 27, 2025

VitalHub Corp. announced the results of its annual general meeting, where all director nominees were elected to the board, and MNP LLP was appointed as auditors. The meeting saw a 60.45% participation rate of the total shares issued and outstanding. These developments reinforce VitalHub’s governance structure and ensure continued oversight and financial integrity, which are crucial for its ongoing growth and market positioning.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
VitalHub Completes Strategic Acquisition of Induction Healthcare
Positive
Jun 19, 2025

VitalHub has completed the acquisition of Induction Healthcare Group PLC, enhancing its product offerings with Induction’s software solutions like Zesty and Attend Anywhere. This acquisition, valued at approximately £9.7 million, is expected to complement VitalHub’s existing solutions, improve healthcare partner value, and enhance patient outcomes, thereby strengthening its position in the healthcare software industry.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

Private Placements and FinancingRegulatory Filings and Compliance
VitalHub Files Preliminary Base Shelf Prospectus for Future Securities Offerings
Neutral
Jun 16, 2025

VitalHub Corp. has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Alberta, British Columbia, and Ontario. This filing, once finalized, will allow the company to qualify the distribution of up to $250 million in various securities over a 25-month period. Although VitalHub has no immediate plans to offer securities under this prospectus, the move positions the company to quickly capitalize on future opportunities, potentially impacting its financial strategy and market positioning.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
VitalHub Achieves Robust Q1 2025 Growth and Eyes Strategic Acquisition
Positive
May 8, 2025

VitalHub Corp. reported significant financial growth in the first quarter of 2025, with a 54% year-over-year increase in Annual Recurring Revenue (ARR) to $73.7 million and a 42% rise in total revenue to $21.7 million. The company is strengthening its infrastructure and exploring strategic acquisitions, including a potential cash acquisition of UK-based Induction Healthcare Group, expected to close in the third quarter of 2025. This acquisition, along with other opportunities in the pipeline, is anticipated to provide strong synergistic value and enhance VitalHub’s market positioning.

Financial Disclosures
VitalHub to Release Q1 2025 Financial Results and Host Conference Call
Neutral
Apr 28, 2025

VitalHub Corp. has announced it will release its Q1 2025 financial results on May 8, 2025, followed by a conference call on May 9, 2025. This announcement is part of VitalHub’s ongoing efforts to engage with stakeholders and provide transparency about its financial performance, which could impact its market positioning and investor relations.

M&A TransactionsBusiness Operations and Strategy
VitalHub Announces Acquisition of Induction Healthcare Group
Positive
Apr 10, 2025

VitalHub Corp. has announced a recommended cash acquisition of Induction Healthcare Group PLC, valuing the company at approximately £9.7 million. This strategic move aims to integrate Induction’s Zesty platform with VitalHub’s existing offerings, enhancing product efficiency and user experience. The acquisition is expected to expand VitalHub’s geographic reach and improve patient outcomes across key markets. Induction’s directors have unanimously recommended shareholders to vote in favor of the acquisition, which requires court approval and shareholder agreement.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025